FDA approves Samsung Bioepis biosimilar.
Veliparib fails in two phase 3 trials.
UK firm lays down the gauntlet in the PARP inhibitor battle.
Cambridge firm played key role in discovery of potential blockbuster Kisqali.
Companies hope to challenge traiblazers Novartis and Kite.
Experts call for shake-up of EU regulation.
Analysis questions industry’s rationale for high US prices.
Merck and Pfizer have Boehringer and Lilly in their sights with ertugliflozin
US authorities probing several other drugmakers amid pricing row.